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1. INTRODUCTION {#jpn13129-sec-0001}
===============

Weaning triggers significant psychosocial, and physical, stress in piglets including maternal and littermate separation, and abrupt diet change (Campbell, Crenshaw, & Polo, [2013](#jpn13129-bib-0005){ref-type="ref"}; Qiao, Li, Wang, & Wang, [2015](#jpn13129-bib-0030){ref-type="ref"}; Xiong et al., [2015](#jpn13129-bib-0040){ref-type="ref"}). Abrupt weaning can contribute to intestinal and immune system dysfunctions and lead to diarrhoea (Kuang et al., [2015](#jpn13129-bib-0023){ref-type="ref"}; Pluske, Hampson, & Williams, [1997](#jpn13129-bib-0028){ref-type="ref"}). In order to address problems caused by weaning, antibiotics have been widely used (Cromwell, [2002](#jpn13129-bib-0010){ref-type="ref"}; Yin et al., [2009](#jpn13129-bib-0044){ref-type="ref"}). Misuse of antibiotics in feed has resulted in serious complications due to drug residues in animal products and increased bacterial resistance (Yen, Lai, Lin, & Chiang, [2015](#jpn13129-bib-0043){ref-type="ref"}). Dietary antibiotics change enteric microflora that are important maintaining intestinal health and function (Guarner & Malagelada, [2003](#jpn13129-bib-0013){ref-type="ref"}).

IgY derived from egg yolks by immunizing hens. It is actively transported from hen serum into the embryo via the egg yolk and provides passive immunity to embryos and offspring (Muller, Schubert, Zajac, Dyck, & Oelkrug, [2015](#jpn13129-bib-0026){ref-type="ref"}; Sui, Cao, & Lin, [2011](#jpn13129-bib-0031){ref-type="ref"}). IgY is resistant against specific pathogens based on the antigen the hens are immunized against. It has been shown to be effective against a variety of intestinal pathogens particularly diarrhoea pathogens such as bovine and human rotaviruses, bovine coronavirus, enterotoxigenic *Escherichia coli* (ETEC) and *Salmonella* (Diraviyam et al., [2014](#jpn13129-bib-0011){ref-type="ref"}; Muller et al., [2015](#jpn13129-bib-0026){ref-type="ref"}; Sui et al., [2011](#jpn13129-bib-0031){ref-type="ref"}; Thu et al., [2017](#jpn13129-bib-0032){ref-type="ref"}; Xu et al., [2011](#jpn13129-bib-0041){ref-type="ref"}). IgY has attracted considerable interest as an alternative to antibiotics for the control of infectious diseases in the alimentary tract (Li, Wang, Zhen, Li, & Xu, [2015](#jpn13129-bib-0025){ref-type="ref"}). The present study was conducted to test the hypothesis that supplementing early weaned piglet (EWP) diets with anti‐*E. coli* IgY may affect their enteric *Escherichia coli*, without affecting other micro‐organisms, and also beneficially intestinal function.

2. MATERIALS AND METHODS {#jpn13129-sec-0002}
========================

2.1. Animals, housing and experimental treatments {#jpn13129-sec-0003}
-------------------------------------------------

One hundred and forty‐eight (148) (\[Landrace × Yorkshire\] × Duroc) piglets were weaned day 21. Their initial body weight (BW) was 7.37 ± 0.26 kg. They were used in a 14‐day feeding trial. EWPs were assigned to one of three possible treatments (3 replicate/treatment; 13--17 piglets/replicate). They were the control group (base diet), the antibiotics group (base diet + 100 ppm colistin sulphate + 15 ppm enramycin) and the IgY group (base diet + 500 ppm specific IgY). The base diet formulation (Table [1](#jpn13129-tbl-0001){ref-type="table"}) met nutrient requirements of weaned pigs as recommended by the National Research Council (NRC, [2012](#jpn13129-bib-0027){ref-type="ref"}). Specific IgY with high titres of anti‐*E. coli* (50 000) was provided by Zyme Fast (Changsha) Biotechnology. Throughout the experimental period, feed and water were available ad libitum. At the end of the trial, seven EWPs from each group were randomly selected and sacrificed for sampling. The experimental design and procedures in this study were reviewed and approved by the Animal Care and Use Committee of Hunan Normal University, Changsha City, Hunan, China.

###### 

Diet composition as fed

  Component                                                        Content (%)
  ---------------------------------------------------------------- -------------
  Corn                                                             37.66
  Extruded corn                                                    20.00
  Soybean meal, 43% CP                                             8.00
  Concentrated soy protein                                         7.00
  Whey                                                             10.00
  Fish meal, 63% CP                                                5.00
  Plasma protein powder                                            4.50
  [l]{.smallcaps}‐lysine HCl, 98%                                  0.33
  [dl]{.smallcaps}‐methionine                                      0.08
  [l]{.smallcaps}‐threonine                                        0.03
  [l]{.smallcaps}‐tryptophan                                       0.01
  Glucose                                                          2.00
  Soybean oil                                                      2.00
  Limestone                                                        1.04
  Monocalcium phosphate                                            0.50
  Choline chloride, 50%                                            0.10
  Antioxidants                                                     0.05
  Zinc oxide                                                       0.30
  Citric acid                                                      0.30
  Vitamin--mineral premix[a](#jpn13129-note-0003){ref-type="fn"}   1.00
  IgY premix or carrier[b](#jpn13129-note-0004){ref-type="fn"}     0.10
  Total                                                            100
  Calculated composition                                           
  CP, %                                                            18.0
  ME, MJ/kg                                                        14.2
  Lysine[c](#jpn13129-note-0005){ref-type="fn"} %                  1.35
  Methionine[c](#jpn13129-note-0005){ref-type="fn"} %              0.39
  Methionine + cystine[c](#jpn13129-note-0005){ref-type="fn"} %    0.74
  Threonine[c](#jpn13129-note-0005){ref-type="fn"} %               0.79
  Tryptophan[c](#jpn13129-note-0005){ref-type="fn"} %              0.22

Abbreviations: CP, crude protein; ME, metabolizable energy.

Vitamin--mineral premix supplied per kilogram of feed: 10,000 IU of vitamin A, 1,000 IU of vitamin D~3~, 80 IU of vitamin E, 2.0 mg of vitamin K~3~, 0.03 mg of vitamin B~12~, 12 mg of riboflavin, 40 mg of niacin, 25 mg of d‐pantothenic acid, 0.25 mg of biotin, 1.6 mg of folic acid, 3.0 mg of thiamine, 2.25 mg of pyridoxine, 300 mg of choline chloride, 150 mg of Fe (FeSO~4~), 100 mg of Zn (ZnSO~4~), 30 mg of Mn (MnSO~4~), 25 mg of Cu (CuSO~4~), 0.5 mg of I (KIO~3~), 0.3 mg of Co (CoSO~4~), 0.3 mg of Se (Na~2~SeO~3~) and 4.0 mg of ethoxyquin.

IgY = chicken egg yolk immunoglobulins; dried, egg yolk powder spray was used as carrier.

Standardized ileal digestible.
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2.2. Growth performance and diarrhoea rate {#jpn13129-sec-0004}
------------------------------------------

Initial and final body weight and feed consumption were recorded throughout the trial. Average daily gain (ADG), average daily feed intake (ADFI) and feed/gain (F:G) ratio were calculated. Each pig was clinically monitored throughout the experiment. Diarrhoea score was recorded as (0), normal; (1), soft; (2), mild diarrhoea; and (3), severe diarrhoea (watery stool) (Alustiza et al., [2016](#jpn13129-bib-0002){ref-type="ref"}). Diarrhoea rate was calculated according to this formula. Diarrhoea rate (%) = number of EWPs with diarrhoea within a treatment/(number of EWPs × total experimental days) × 100%. "Number of EWPs with diarrhoea" was the total number of EWPs with diarrhoea observed on a particular day (Wan et al., [2016](#jpn13129-bib-0036){ref-type="ref"}).

2.3. Collection of serum, digesta and jejunal mucosal samples {#jpn13129-sec-0005}
-------------------------------------------------------------

Blood was sampled via 10‐ml vacutainer tubes that contained EDTA as an anticoagulant. They were centrifuged at 3,000 × *g* for 10 min at 4°C (Yin et al., [2009](#jpn13129-bib-0044){ref-type="ref"}) and stored at −80°C until the biochemical profile analysis was performed. Total protein (TP), alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), glucose (GLU), triglycerides (TG), cholesterol (CHOL), high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), diamine oxidase (DAO), Complement C~4~, immunoglobulin M (IgM) and NH~3~ in serum were examined. Digesta samples from the ileum, caecum and colon were collected, quick‐frozen in liquid nitrogen and stored at −80°C (Kuang et al., [2015](#jpn13129-bib-0023){ref-type="ref"}). Mid‐jejunum intestinal tissues (approximately 20 cm) were collected. Mucosa samples were scraped using sterilized glass slides, frozen in liquid nitrogen and stored at ‐80°C for further processing (Xiong et al., [2015](#jpn13129-bib-0040){ref-type="ref"}).

2.4. RNA isolation and real‐time quantitative PCR analysis {#jpn13129-sec-0006}
----------------------------------------------------------

Total RNA was isolated from jejunal mucosal samples using a TRIzol reagent (100 mg tissue per 1 ml TRIzol; Invitrogen Life Technologies) following manufacturer instructions. RNA integrity was checked using 1% agarose gel electrophoresis stained with 10 µg/ml ethidium bromide. The quantity and quality of RNA were determined using a NanoDrop ND‐2000 spectrophotometer system (Thermo Fisher Scientific). All RNA samples were reverse transcribed into cDNA using a Superscript First‐Strand Synthesis System (Invitrogen Life Technologies) with a PrimeScript RT‐PCR kit (TaKaRa) using OligodT Primer. cDNA samples were then tested for *IL‐1β*, *IL‐6*, *IFN‐r*, *TNF‐α*, *ZO‐1*, *Claudin‐1* and *Occludin‐1* expressions via real‐time RT‐PCR performed as described by Yang, Wang, Xiong, and Yin ([2016](#jpn13129-bib-0042){ref-type="ref"}). Results were normalized to *β‐actin* expression. Relative quantification was calculated using the 2^−ΔΔCT^ method. The sequences for the sense and antisense primers used to quantify mRNA were designed using Oligo 6.0 (Molecular Biology Insights) and appear in Table [2](#jpn13129-tbl-0002){ref-type="table"}.

###### 

Cytokines primers and tight junction proteins used

  Target gene   Orientation               Sequence (5′--3′)       *T* ~m~ (°C)   Product size (bp)
  ------------- ------------------------- ----------------------- -------------- -------------------
  *β‐actin*     Forward                   AGTTGAAGGTGGTCTCGTGG    57.4           216
  Reverse       TGCGGGACATCAAGGAGAAG                                             
  *IL‐1β*       Forward                   CCTGGACCTTGGTTCTCT      53             123
  Reverse       GGATTCTTCATCGGCTTCT                                              
  *IL‐6*        Forward                   GGCAAAAGGGAAAGAATCCAG   57             87
  Reverse       CGTTCTGTGACTGCAGCTTATCC                                          
  *IFN‐r*       Forward                   CCATTCAAAGGAGCATGGAT    55             146
  Reverse       GAGTTCACTGATGGCTTTGC                                             
  *TNF‐α*       Forward                   ACAGGCCAGCTCCCTCTTAT    53.9           102
  Reverse       CCTCGCCCTCCTGAATAAAT                                             
  *ZO‐1*        Forward                   TTGATAGTGGCGTTGACA      52             126
  Reverse       CCTCATCTTCATCATCTTCTAC                                           
  *Claudin‐1*   Forward                   CTAGTGATGAGGCAGATGAA    59             250
  Reverse       AGATAGGTCCGAAGCAGAT                                              
  *Occludin*    Forward                   GAGTGATTCGGATTCTGTCT    54             181
  Reverse       TAGCCATAACCATAGCCATAG                                            

Abbreviations: *IL‐1β*, interleukin 1β; *IL‐6*, interleukin 6; *IFN‐r*, interferon‐γ; Tm, melting temperature; *TNF‐α*, tumour necrosis factor alpha; *ZO‐1*, Zonula occludens‐1.
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2.5. Bacterial quantification by real‐time PCR {#jpn13129-sec-0007}
----------------------------------------------

Intestinal digesta samples were collected after sacrifice. Total bacteria DNA was extracted using a QIAamp DNA stool mini kit (Qiagen) following manufacturer\'s instructions. DNA concentration and quality were checked using NanoDrop ND‐2000 spectrophotometer system (Fisher Scientific) prior to the samples being adjusted to a concentration of 10 ng/µl. *Enterococcus*, *E. coli*, *Lactobacillus*, *Clostridium*, *Bifidobacterium* and enterotoxins quantifications were conducted using real‐time PCR, according to the methods described in Wang, Zijlstra, and Ganzle ([2017](#jpn13129-bib-0037){ref-type="ref"}). Results were normalized total bacteria expression and relative fold changes calculated by the 2^−ΔΔCT^ method. PCR primers are listed in Table [3](#jpn13129-tbl-0003){ref-type="table"}.

###### 

Primers used to amplify bacteria and enterotoxins in digesta samples

  Target gene          Orientation               Sequence (5′--3′)            *T* ~m~ (°C)   Product size (bp)
  -------------------- ------------------------- ---------------------------- -------------- -------------------
  *Total bacteria*     Forward                   CGGTCCAGACTCCTACGGG          63             200
  Reverse              TTACCGCGGCTGCTGGCAC                                                   
  *Enterococcus*       Forward                   CCCTTATTGTTAGTTGCCATCATT     63             144
  Reverse              ACTCGTTGTACTTCCCATTGT                                                 
  *Escherichia coli*   Forward                   CCGATACGCTGCCAATCAGT         65             884
  Reverse              ACGCAGACCGTAGGCCAGAT                                                  
  *Lactobacillus*      Forward                   AGCAGTAGGGAATCTTCCA          59             341
  Reverse              CACCGCTACACATGGAG                                                     
  *Clostridium*        Forward                   AATGACGGTACCTGACTAA          63             439
  Reverse              CTTTGAGTTTCATTCTTGCGAA                                                
  *Bifidobacterium*    Forward                   CGCGTCCGGTGTGAAAG            51             121
  Reverse              CTTCCCGATATCTACACATTCCA                                               
  *Heat‐labile*        Forward                   CCGTGCTGACTCTAGACCCCCA       68             480
  *Enterotoxin*        Reverse                   CCTGCTAATCTGTAACCATCCTCTGC                  
  *Heat‐stable*        Forward                   TGCCTATGCATCTACACAAT         63             110
  *Enterotoxin b*      Reverse                   CTCCAGCAGTACCATCTCTA                        

Abbreviation: *T* ~m~, melting temperature.
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2.6. Statistical analysis {#jpn13129-sec-0008}
-------------------------

Results were expressed as mean ± *SEM*. Statistical differences were determined using one‐way ANOVA with [spss]{.smallcaps} 22.0 software (SPSS). Duncan differences were determined to compare differences among the groups. Values were considered significantly different at *p* \< 0.05, while 0.05 \< *p* \< 0.10 was used to indicate a tendency towards significance.

3. RESULTS {#jpn13129-sec-0009}
==========

3.1. Growth performance and diarrhoea rates {#jpn13129-sec-0010}
-------------------------------------------

Early weaned piglet growth during the 14‐day experimental period appears in Table [4](#jpn13129-tbl-0004){ref-type="table"}. ADG, ADFI and F:G were similar for all dietary treatments. EWPS fed antibiotic‐containing diets had lower (*p* \< 0.05) diarrhoea rates than controls. There were no diarrhoea rate differences between antibiotic‐treated and IgY‐fed EWPs.

###### 

Effects of antibiotics or IgY on early weaned piglet growth

  Item                  Control           Antibiotics        IgY               *p*‐Values
  --------------------- ----------------- ------------------ ----------------- ------------
  Initial weight/kg     7.38 ± 0.73       7.36 ± 0.28        7.37 ± 0.44       0.999
  Final weight/kg       8.35 ± 0.75       8.38 ± 0.25        8.58 ± 0.28       0.938
  ADG (g/day)           69.34 ± 9.47      73.04 ± 6.94       86.66 ± 33.87     0.958
  ADFI (g/day)          197.28 ± 36.52    210.39 ± 5.23      171.33 ± 18.25    0.252
  F:G                   2.82 ± 0.26       2.93 ± 0.3         2.43 ± 0.58       0.674
  Diarrhoea ratio (%)   3.7 ± 0.53^a^     1.51 ± 0.57^b^     3.15 ± 0.84^ab^   0.020
  Diarrhoea index       0.079 ± 0.01^a^   0.032 ± 0.014^b^   0.07 ± 0.02^ab^   0.049

Values are expressed as mean ± *SEM*, *n* = 3.

Abbreviations: ADG, average daily gain; ADFI, average daily feed intake; F:G, feed/gain.

Means within each row, values not labelled with the same superscript letters are significantly different at *p* \< 0.05 or show a tendency towards differing at *p* \< 0.10.
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3.2. Serum biochemical indexes {#jpn13129-sec-0011}
------------------------------

Serum biochemical analysis showed that EWPs fed an IgY‐containing diet had lower (*p* \< 0.05) CHOL and LDL than did antibiotic‐treated EWPs. There were no differences in serum TP, ALT, AST, BUN, GLU, TG, HDL, DAO, C~4~, IgM or NH~3~ among the three treatment groups (Table [5](#jpn13129-tbl-0005){ref-type="table"}).

###### 

EWP serum biochemical profiles

  Item            Control           Antibiotics      IgY              *p*‐Values
  --------------- ----------------- ---------------- ---------------- ------------
  TP (g/L)        49.01 ± 1.25      50.17 ± 0.63     52.00 ± 1.27     0.187
  ALT (U/L)       41.41 ± 4.91      36.31 ± 1.83     35.41 ± 3.47     0.467
  AST (U/L)       52 ± 4.71         48.5 ± 4.42      50.2 ± 4.88      0.867
  BUN (mmol/L)    3.99 ± 0.37       4.36 ± 0.19      4.11 ± 0.35      0.703
  GLU (mmol/L)    6.71 ± 0.47       6.7 ± 0.40       5.41 ± 0.55      0.116
  TG (mmol/L)     0.53 ± 0.04       0.56 ± 0.05      0.54 ± 0.04      0.858
  CHOL (mmol/L)   1.93 ± 0.12^ab^   2.28 ± 0.16^a^   1.76 ± 0.12^b^   0.039
  HDL (mmol/L)    0.85 ± 0.09       0.99 ± 0.07      0.73 ± 0.07      0.108
  LDL (mmol/L)    1.02 ± 0.06^ab^   1.23 ± 0.10^a^   0.93 ± 0.07^b^   0.036
  DAO (mmol/L)    1.43 ± 0.24       1.34 ± 0.16      1.1 ± 0.09       0.663
  C~4~ (g/L)      0.03 ± 0.001      0.03 ± 0.004     0.03 ± 0.002     0.605
  IgM (g/L)       0.56 ± 0.04       0.53 ± 0.06      0.57 ± 0.06      0.854
  NH~3~(µmol/L)   306 ± 22.82       301.83 ± 15.99   261.56 ± 10.37   0.156

Values are expressed as mean ± *SEM*, *n* = 7.

Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; C4, Complement C4; CHOL, cholesterol; DAO, diamine oxidase; GLU, glucose; HDL, high‐density lipoprotein; IgM, immunoglobulin M; LDL, low‐density lipoprotein; NH3, ammonia; TG, triglycerides; TP, total protein.

Means within each row, values not labelled with the same superscript letters are significantly different at *p* \< 0.05 or show a tendency towards differing at *p* \< 0.10.
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3.3. Gene expression of pro‐inflammatory cytokine and tight junction protein in jejunal mucosa {#jpn13129-sec-0012}
----------------------------------------------------------------------------------------------

*IL‐1β* gene expression decreased (*p* \< 0.1) in the groups receiving antibiotics compared to the control group and the IgY group. There were no significant differences in the mRNA expression of pro‐inflammatory cytokines (*IL‐6*, *IFN‐r* and *TNF‐α*). Tight junction proteins (*ZO‐1*, *Claudin‐1* and *Occludin‐1*) were observed in all treatment groups (Table [6](#jpn13129-tbl-0006){ref-type="table"}).

###### 

Gene expression in jejunal mucosa of inflammatory profiles and tight junction proteins

  Item           Control       Antibiotics   IgY           *p*‐Values
  -------------- ------------- ------------- ------------- ------------
  *IL‐1β*        1.04 ± 0.10   0.59 ± 0.15   0.81 ± 0.13   0.071
  *IL‐6*         1.06 ± 0.13   0.69 ± 0.12   1.01 ± 0.26   0.340
  *IFN‐r*        1.09 ± 0.21   1.44 ± 0.41   1.32 ± 0.28   0.803
  *TNF‐α*        1.06 ± 0.10   0.98 ± 0.24   0.88 ± 0.17   0.624
  *Z0‐1*         1.07 ± 0.15   1.01 ± 0.07   1.16 ± 0.09   0.595
  *Claudin‐1*    1.20 ± 0.26   1.26 ± 0.14   1.38 ± 0.23   0.828
  *Occludin‐1*   1.09 ± 0.18   1.04 ± 0.19   1.05 ± 0.15   0.984

Values are expressed as mean ± *SEM*, *n* = 7.

Abbreviations: *IL‐1β*, interleukin 1β; *IL‐6*, interleukin 6; *INF‐r*, interferon‐γ; *TNF‐α*, tumour necrosis factor alpha; *ZO‐1*, Zonula occludens‐1.
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3.4. Intestinal bacterial population changes {#jpn13129-sec-0013}
--------------------------------------------

In‐feed antibiotics significantly decreased (*p* \< 0.05) *E. coli* and *Lactobacillus* populations as well as heat‐stable enterotoxin b (STb) expression in ileal contents compared to the control group (Table [7](#jpn13129-tbl-0007){ref-type="table"}). *E. coli* population significantly (*p* \< 0.05) reduced in IgY‐fed EWP ileal contents compared to the control group. *Enterococcus*,*Lactobacillus*, *Clostridium*, *Bifidobacterium* populations as well as enterotoxin expressions were unaffected by IgY treatment. Dietary antibiotics significantly decreased (*p* \< 0.05) *E. coli* and *Lactobacillus* in caecal digesta as well as STb expression levels compared to the control group (*p* \< 0.05). Greater (*p* \< 0.05) *Enterococcus* populations and lower (*p* \< 0.05) STb expression levels were observed in EWPs fed IgY compared to the control diet (*p* \< 0.05). *Lactobacillus* expression levels in colonic digesta significantly decreased (*p* \< 0.05) in EWPs fed diets containing antibiotics compared to the control group. No significant differences in bacterial populations in IgY group colonic contents were measured compared to the control group.

###### 

Changes in early weaned piglet intestinal bacterial populations

  Item                        Control          Antibiotics      IgY               *p*‐Values
  --------------------------- ---------------- ---------------- ----------------- ------------
  Ileum                                                                           
  *Enterococcus*              1.17 ± 0.23      0.89 ± 0.34      1.78 ± 0.53       0.293
  *Escherichia coli*          1.20 ± 0.30^a^   0.12 ± 0.05^b^   0.25 ± 0.12^b^    0.018
  *Lactobacillus*             1.06 ± 0.15^a^   0.50 ± 0.28^b^   0.99 ± 0.15^a^    0.040
  *Clostridium*               1.03 ± 0.08      0.92 ± 0.33      1.10 ± 0.31       0.904
  *Bifidobacterium*           1.01 ± 0.13      1.05 ± 0.44      0.98 ± 0.17       0.948
  Heat‐labile enterotoxin     1.27 ± 0.27      0.74 ± 0.40      1.75 ± 0.63       0.203
  Heat‐stable enterotoxin b   1.17 ± 0.26^a^   0.25 ± 0.18^b^   0.73 ± 0.24^ab^   0.039
  Caecum                                                                          
  *Enterococcus*              1.11 ± 0.20^b^   0.86 ± 0.20^b^   2.01 ± 0.44^a^    0.041
  *Escherichia coli*          1.11 ± 0.22^a^   0.08 ± 0.03^b^   4.22 ± 1.57^a^    0.005
  *Lactobacillus*             1.14 ± 0.22^a^   0.31 ± 0.14^b^   1.75 ± 0.38^a^    0.002
  *Clostridium*               1.05 ± 0.13      0.84 ± 0.20      0.75 ± 0.11       0.340
  *Bifidobacterium*           1.04 ± 0.01      0.86 ± 0.14      0.88 ± 0.15       0.569
  Heat‐labile enterotoxin     1.42 ± 0.60      6.84 ± 2.38      6.34 ± 2.33       0.355
  Heat‐stable enterotoxin b   1.32 ± 0.47^a^   0.39 ± 0.12^b^   0.43 ± 0.17^b^    0.063
  Colon                                                                           
  *Enterococcus*              1.11 ± 0.0.13    1.27 ± 0.51      1.04 ± 0.11       0.581
  *Escherichia coli*          1.22 ± 0.36      0.66 ± 0.35      1.95 ± 0.91       0.195
  *Lactobacillus*             1.45 ± 0.48^a^   0.23 ± 0.11^b^   1.36 ± 0.42^ab^   0.028
  *Clostridium*               1.11 ± 0.16      1.36 ± 0.25      1.06 ± 0.15       0.506
  *Bifidobacterium*           1.13 ± 0.18      1.40 ± 0.22      1.01 ± 0.17       0.358
  Heat‐labile enterotoxin     1.35 ± 0.46      3.80 ± 1.41      5.30 ± 1.77       0.344
  Heat‐stable enterotoxin b   1.14 ± 0.30      1.53 ± 0.94      1.70 ± 0.70       0.926

Values are expressed as mean ± *SEM*, *n* = 7.

Means within each row, values not labelled with the same superscript letters are significantly different at *p* \< 0.05 or show a tendency towards differing at *p* \< 0.10.
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4. DISCUSSION {#jpn13129-sec-0014}
=============

Enterotoxigenic *E. coli* is a major cause of diarrhoea and death in neonatal and EWPs (Wu et al., [2012](#jpn13129-bib-0039){ref-type="ref"}). *E. coli* can adhere to the intestinal epithelial cells and elaborate enterotoxins (LT, STa or STb). This induces diarrhoea and intestinal inflammation (Heo et al., [2013](#jpn13129-bib-0014){ref-type="ref"}; Wang et al., [2017](#jpn13129-bib-0037){ref-type="ref"}). In the experiments described here, dietary supplementation of antibiotics or *E. coli* K88‐specific IgY had no effect on ADG or ADFI compared to the control group. Heo et al. ([2015](#jpn13129-bib-0015){ref-type="ref"}) reported that egg antibodies did not significantly affect growth performance in 21‐day‐old EWPs in the first phase (14‐day period and unchallenged) of the investigation.

It has been reported that pro‐inflammatory cytokines, such as *TNF‐α*, *IFN‐r*, *IL‐6* and *IL‐1β*, play a crucial role in the modulating inflammatory response (Al‐Sadi, Boivin, & Ma, [2009](#jpn13129-bib-0001){ref-type="ref"}) and also participate in intestinal barrier integrity regulation (Hu, Xiao, Luan, & Song, [2013](#jpn13129-bib-0018){ref-type="ref"}; Wang et al., [2016](#jpn13129-bib-0038){ref-type="ref"}). The present study analysed gene expressions of pro‐inflammatory cytokines and tight junction proteins in the EWP intestines. No significant differences were observed. This demonstrates that adding antibiotics or IgY to diets results in no differences in intestinal inflammatory responses or intestinal barrier integrity.

Digestive system microflora play important roles in maintaining intestinal health and function (Dowarah, Verma, & Agarwal, [2017](#jpn13129-bib-0012){ref-type="ref"}). A previous study on intestinal microbiota of weaned piglets has shown that after weaning, *E. coli* concentrations increased while the number of *Lactobacillus* decreased (Konstantinov et al., [2006](#jpn13129-bib-0022){ref-type="ref"}). As we know, *E. coli* is one of the major sources of intestinal pathogens, and a few strains can induce serious illness, including diarrhoea (Hu et al., [2014](#jpn13129-bib-0019){ref-type="ref"}). The improvement of the immunoglobulins is required to regulate and enhance immune function, which provides health benefits, diminished weaning stress and improved health status and performance of weaning pigs. This study detected significantly decreased *E. coli* in ileal digesta in IgY‐fed EWPs and antibiotic‐fed EWPs compared to controls. This suggests that IgY has the similar effect to antibiotic against *E. coli*. Antibiotic feed reduced *E. coli* populations in the caecum which is consistent with Wu et al. ([2012](#jpn13129-bib-0039){ref-type="ref"}), who reported that antibiotics reduced *E. coli* populations in the caecum compared to control EWPs. Dietary IgY supplements increased *Lactobacillus* population in the ileum and caecum compared with the antibiotic group and significantly decreased enterotoxin STb in caecum digesta compared to the control group. These results show that the inclusion of antibiotic in the diet reduced the proliferation of both harmful coliform bacteria and beneficial *Lactobacillus* in the pig\'s gut. Antibiotics seriously affect the activity and composition of the gut microflora. It is reported that most cases of antibiotic‐associated diarrhoea (AAD) may be due to direct toxics effects of antibiotics on the intestine, altered digestive function secondary to reduced concentrations of gut bacteria or overgrowth of pathogenic micro‐organisms (Beaugerie & Petit, [2004](#jpn13129-bib-0003){ref-type="ref"}). Additionally, it has been reported that an increment of *Lactobacillus* results in competitively exclude potentially pathogenic species from colonizing the intestine (Collier et al., [2003](#jpn13129-bib-0009){ref-type="ref"}). In our study, *Clostridium* and *Bifidobacterium* are not affected by IgY supplementation.

In healthy intestinal tracts, *Lactobacillus* dominates (Dowarah et al., [2017](#jpn13129-bib-0012){ref-type="ref"}). *Lactobacillus* is considered to produce lactate from sugars as the only or major end product with some minor products such as acetate, formate or ethanol (Tsukahara & Ushida, [2002](#jpn13129-bib-0035){ref-type="ref"}). Previous studies demonstrated *Lactobacillus* potential to increase beneficial bacteria and inhibit pathogenic bacteria (Hossain, Begum, & Kim, [2015](#jpn13129-bib-0017){ref-type="ref"}; Qi et al., [2011](#jpn13129-bib-0029){ref-type="ref"}). *Lactobacillus* produced lactic acid, hydrogen peroxide and lactoferrin which may exhibit antagonistic activity against *E. coli* (Li, Ni, et al., [2015](#jpn13129-bib-0024){ref-type="ref"}). IgY supplementation significantly decreased cholesterol and low‐density lipoprotein concentrations and confirms this positive effect of IgY. Jeon, Kang, Kim, Hwangbo, and Park ([2016](#jpn13129-bib-0020){ref-type="ref"}) reported findings consistent with this report that IgY significantly decreases total cholesterol compared to the control group. The decreased cholesterol concentration could be attributed to assimilation (or uptake) by *Lactobacillus* (Buck & Gilliland, [1994](#jpn13129-bib-0004){ref-type="ref"}) or to coprecipitate of cholesterol with deconjugated bile salts (Jin, Ho, Abdullah, & Jalaludin, [1998](#jpn13129-bib-0021){ref-type="ref"}). Chen, Wang, Yan, and Huang ([2013](#jpn13129-bib-0007){ref-type="ref"}) reported probiotics reduced serum cholesterol and inhibit hydroxyl‐methyl‐glutaryl coenzyme‐A, which is involved in cholesterol synthesis. Thus, the decreased cholesterol concentration could be attributed to the reduced synthesis of cholesterol. Low‐density lipoprotein (LDL) is also referred to as "bad" cholesterol, because it constitutes a major risk factor for cardiovascular disease (Toth et al., [2013](#jpn13129-bib-0034){ref-type="ref"}).

In order to prevent or treat enteric infections, IgY must resist degradation and reach the small intestine without activity loss (Hong et al., [2004](#jpn13129-bib-0016){ref-type="ref"}). Several strategies to protect IgY from hydrolysis have been developed including liposomes (Chang, Lee, Chen, & Tu, [2002](#jpn13129-bib-0006){ref-type="ref"}), polymeric microspheres (Torche et al., [2006](#jpn13129-bib-0033){ref-type="ref"}) and multiple emulsifications (Cho et al., [2005](#jpn13129-bib-0008){ref-type="ref"}). Further investigations are indispensable to determine how robust of IgY application can be. Optimizing IgY dose effectiveness via a suitable formulation to withstand the gastric environment is warranted, and we hope explore any synergistic effects of combining IgY with other therapeutic strategies, such as probiotics or plant extracts in order to improve performance.

5. CONCLUSION {#jpn13129-sec-0015}
=============

In this work, dietary supplementation with IgY has the potential to suppress the growth of bacterial pathogens, thus promoting and maintaining a healthy EWP intestinal environments. These findings suggest that IgY may be used as an alternative to the use of antibiotics in diets for weaned EWPs.
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